| Field | Specification |
|---|---|
| Target | |
| Alternative names | Signal transducer and activator of transcription 3;Acute-phase response factor;STAT3;APRF; |
| UniProt # | |
| Host | |
| Clone | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | A synthesized peptide derived from human STAT3 |
| Molecular weight | |
| Purification | |
| Cellular localization | |
| Concentration | |
| Form | Liquid |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Product Overview
Clone IFA-19 is a rabbit monoclonal antibody that recognizes signal transducer and activator of transcription 3 (gene STAT3) phosphorylated at Tyr705 in human, mouse and rat samples and is validated for Western blot, IHC, ICC/IF and immunoprecipitation. The predicted molecular weight is 88.1 kDa, and the supplier reports an observed band at about 88 kDa.
STAT3 is a transcription factor activated mainly by IL-6-family cytokines through gp130 and JAK kinases, and also by growth factors and leptin. Phosphorylated STAT3 dimerizes, enters the nucleus and regulates genes for acute-phase responses, cell survival and proliferation. It shapes Th17 differentiation and is persistently active in many cancers, making it a major research target.
| Target | Signal transducer and activator of transcription 3 (gene STAT3; UniProt P40763, human) — phosphorylated at Tyr705 |
|---|---|
| Clone | IFA-19 |
| Host / Clonality / Isotype | Rabbit / Monoclonal / Rabbit IgG |
| Reactivity | Human, Mouse, Rat |
| Form | Liquid |
| Formulation | PBS (pH 7.4); 150 mM NaCl; 0.02% sodium azide; 50% glycerol; plus stabilizers |
| Calculated MW | 88.1 kDa |
| Observed MW | 88 kDa |
| Storage | Long term: −20 °C for up to 12 months. Frequent use: 4 °C for up to 1 month. Avoid repeated freeze–thaw cycles. |
Validated Applications
| Western blot | 1:1000–1:5000 |
|---|---|
| Immunohistochemistry | 1:50–1:200 |
| Immunocytochemistry / Immunofluorescence | 1:50–1:200 |
| Immunoprecipitation | 1:30 |
Samples with a confirmed band (WB): human HeLa cells, mouse NIH/3T3 cells, mouse RAW264.7 cells.
Recommended loading (WB): 20–40 µg of total protein per lane.
Conditions in the example images (WB): 5–20% gradient SDS-PAGE under reducing conditions, 30 µg lysate per lane, transfer to nitrocellulose membrane, blocking in 5% non-fat milk, primary antibody at 1:5000 overnight at 4 °C, HRP-conjugated secondary antibody at 1:5000, ECL detection.
Samples with confirmed staining (IHC): human lung cancer tissue.
Recommended antigen retrieval: heat-mediated, in TE buffer (pH 9.0); citrate buffer (pH 6.0) can be used instead.
Conditions in the example images (IHC): heat-mediated antigen retrieval in EDTA buffer (pH 8.0).
Samples with confirmed staining (ICC/IF): HeLa cells.
Immunogen
Synthetic peptide based on the sequence of human STAT3.
Reactivity Notes
The supplier lists reactivity with human, mouse and rat. UniProt places signal transducer and activator of transcription 3 in the cytoplasm and nucleus. Tissue expression noted by UniProt (human): Heart, brain, placenta, lung, liver, skeletal muscle, kidney and pancreas. The samples tested by the supplier (listed above) are a practical starting point for positive controls. Because the antibody is phospho-specific, signal depends on the phosphorylation state of the sample; a phosphatase-treated lysate is a useful negative control.
Safety
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
Cuiqing Xie et al. (2026) Synergistic Antitumor Activity and Neuroprotective Effects of FGF1/FGFR Inhibition with Oxaliplatin Chemotherapy. Journal of Advanced Research. 10.1016/j.jare.2026.02.005
Yu Yang et al. (2025) Engineered Panax notoginseng polysaccharide micelles inhibit macrophage polarization and delay the progression of rheumatoid arthritis via JAK2-STAT3 signaling pathway. Journal of Nanobiotechnology. 10.1186/s12951-025-03576-8
Bing Xiao et al. (2024) In situ formed reactive oxygen species-responsive dipyridamole prodrug hydrogel: Spatiotemporal drug delivery for chemoimmunotherapy. Journal of Controlled Release. 10.1016/j.jconrel.2024.08.043
Hao Li et al. (2024) Somatic PDGFRB activating variants promote smooth muscle cell phenotype modulation in intracranial fusiform aneurysm. Journal of Biomedical Science. 10.1186/s12929-024-01040-7
Huichao Zhao et al. (2022) Folic acid intervention changes liver Foxp3 methylation and ameliorates the damage caused by Th17/Treg imbalance after long-term alcohol exposure. Food & Function. 10.1039/D1FO04267J
Chunyan Zhang et al. (2022) Overexpression of miR-125a-5p Inhibits Hepatocyte Proliferation through the STAT3 Regulation In Vivo and In Vitro. International Journal of Molecular Sciences. 10.3390/ijms23158661
Deng Zhicheng et al. (2022) Curcumin and its nano-formulations: Defining triple-negative breast cancer targets through network pharmacology, molecular docking, and experimental verification. Frontiers in Pharmacology. 10.3389/fphar.2022.920514
Ying Shen et al. (2025) Synergistic effects of diammonium glycyrrhizinate and Vitamin D3 against EMT in pulmonary fibrosis through modulating the crosstalk of STAT3/HSP90AA1 and HIF-1α pathway. Journal of Ethnopharmacology. 10.1016/j.jep.2025.120649
Changyu Lei et al. (2025) Pharmacodynamic substances and molecular mechanisms of Tsantan Sumtang alleviating hypoxic pulmonary vascular remodeling. Journal of Ethnopharmacology. 10.1016/j.jep.2025.120585
Vitali E. et al. (2023) The direct impact of pegvisomant on osteoblast functions and bone development. Journal of Endocrinological Investigation. 10.1007/s40618-023-02281-3
